Zhu Zheng, Liang Zhigang, Tong Jichun, Mao Xiaoliang, Yin Yajun, Manor Lydia C, Shen Zhenya
Institute for Cardiovascular Science & Department of Cardiovascular Surgery of the First Affiliated Hospital, Soochow University, China.
Department of Thoracic Surgery, Ningbo First Hospital, Ningbo, Zhejiang 315000, China.
Saudi J Biol Sci. 2018 Jul;25(5):1003-1006. doi: 10.1016/j.sjbs.2018.05.023. Epub 2018 May 22.
Ethnicity differences may contribute to the variety of overall survival in pulmonary adenocarcinoma, while the influence of ethnicity relevant somatic driver mutations (ERSDM) profile on Caucasian survival is not well investigated. In this study, we studied epidermal growth factor receptor (EGFR), tumor protein p53 (TP53), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), and Serine/Threonine Kinase 11 (STK11) to construct the ERSDM profile. Those genes were selected as harboring somatic driver mutations with >10% prevalence and with different occurrence between Caucasian and Asian ethnicity. Clinical information and transcriptome sequencing of 173 Caucasian pulmonary adenocarcinoma patients with matched mutation data are retrieved from TCGA, Kaplan-Meier analyses and Cox proportional-hazards regression models are further used to analyze the effect of the ERSDM profile on overall survival. There is no significant correlation between single gene mutation and overall survival, while patients with less than two mutated genes have a better overall survival compared with those with at least two mutated genes (p = 0.034). All of these indicate that multiple mutations in the ERSDM profile may be a negative prognostic factor for overall survival in Caucasian pulmonary adenocarcinoma patients.
种族差异可能导致肺腺癌总体生存率的差异,而种族相关的体细胞驱动突变(ERSDM)谱对白种人生存率的影响尚未得到充分研究。在本研究中,我们研究了表皮生长因子受体(EGFR)、肿瘤蛋白p53(TP53)、 Kirsten大鼠肉瘤2病毒癌基因同源物(KRAS)和丝氨酸/苏氨酸激酶11(STK11),以构建ERSDM谱。选择这些基因是因为它们携带患病率>10%且在白种人和亚洲种族中发生率不同的体细胞驱动突变。从TCGA数据库中检索了173例具有匹配突变数据的白种人肺腺癌患者的临床信息和转录组测序数据,进一步使用Kaplan-Meier分析和Cox比例风险回归模型来分析ERSDM谱对总体生存的影响。单基因突变与总体生存之间无显著相关性,而与至少有两个基因突变的患者相比,基因突变少于两个的患者总体生存率更高(p = 0.034)。所有这些表明,ERSDM谱中的多个突变可能是白种人肺腺癌患者总体生存的不良预后因素。